Расширенный поиск

Небулайзерная терапия суспензией будесонида при обострениях бронхиальной астмы и хронической обструктивной болезни легких

Полный текст:

Об авторе

С. Н. Авдеев
ФГУ НИИ пульмонологии Росздрава

Список литературы

1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2006 report is available on

2. Global strategy for asthma management and prevention NHLBI/WHO Workshop Report: NIH Publication No 02–3659. The 2006 report is available on

3. International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225–1232.

4. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.

5. Rowe B.H., Keller J.L., Oxman A.D. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am. J. Emerg. Med. 1992; 10: 301–310.

6. Rowe B.H., Bota G.W., Fabris L. et al. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. J. A. M. A. 1999; 281: 2119–2126.

7. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–460.

8. Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. 1999; 340: 1941–1947.

9. Shee C.D. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir. Med. 1990; 84: 229–233.

10. Matsumoto H., Ishihara K., Hasegawa T. et al. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4year longitudinal study. Chest 2001; 120: 1468–1473.

11. Rodrigo G., Rodrigo C. Corticosteroids in the emergency department therapy of acute adult asthma: аn evidencebased evaluation. Chest 1999; 116: 285–295.

12. Pedersen S., O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (suppl. 39): 1–34.

13. Rodrigo G., Rodrigo C. Inhaled flunisolide for acute severe asthma. Am. J. Respir. Crit. Care Med. 1998; 157: 698–703.

14. Rodrigo G.J. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. Chest 2006; 130; 1301–1311.

15. Belda J., Margarit G., Martinez C. et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. Eur. Respir. J. 2007; 30: 1143–1149.

16. Авдеев С.Н. Использование небулайзеров в клинической практике. Рус. мед. журн. 2001; 9 (5): 189–196.

17. Packe G.E., Douglas J.G., McDonald A.F. et al. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992; 47: 414–417.

18. Dolan L.M., Kesarwala H.H., Holroyde J.C., Fischer T.J. Short-term, high-dose, systemic steroids in children with asthma: the effect on the hypothalamic–pituitary–adrenal axis. J. Allergy Clin. Immunol. 1987; 80: 81–87.

19. Henzen C., Suter A., Lerch E. et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355: 542–545.

20. McEvoy C.E., Niewoehner D.E. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732–743.

21. Messer J., Reitman D., Sacks H. et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N. Engl. J. Med. 1983; 309: 21–24.

22. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin. Pharmacol. Ther. 1972; 13: 694–702.

23. Decramer M., Lacquet L.M., Fagard R. et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am. Rev. Respir. Dis. 1994; 150: 11–16.

24. Nava S., Fracchia C., Callegari G. et al. Weakness of respiratory and sceletal muscles after a short course of steroids in patients with acute lung rejection. Eur. Respir. J. 2002; 20: 497–499.

25. Bulpa P.A., Dive A.M., Garrino M.2G. et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med. 2001; 27: 59–67.

26. Bulpa P., Dive A., Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30: 782–800.

27. Aberdein J., Singer M. Clinical review: а systematic review of corticosteroid use in infections. Critical Care 2006, 10: 203 (doi:10.1186/cc3904).

28. Wood2Baker R., Walters J., Walters E.H. Systemic corticosteroids in chronic obstructive pulmonary disease: аn overview of Cochrane systematic reviews. Respir. Med. 2007; 101: 371–377.

29. Nehme O., Rachoin J.2S., Azar M. et al. Glycemic control during inhospital corticosteroid treatment for exaxerbations of obstructive airway disease. Chest Meet. Abstr. 2006; 130: 184S-d–185S-d.

30. Baker E.H., Janaway C.H., Philips B.J. et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284–289.

31. Huiart L., Ernst P., Ranouil X., Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can. Respir. J. 2006; 13: 134–138.

32. Wilson A.M., McFarlane L.C., Lipworth B.J. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest 1998; 114: 1022–1029.

33. Morice A.H., Morris D., Lawson2Matthew P. A comparison of nebulized budesonide wiyth oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin. Pharmacol. Ther. 1996; 60: 675–678.

34. McFadden E.R. Inhaled corticosteroids and acute asthma. Therapeutic breakthrough or nonspecific effect? Am. J. Respir. Crit. Care Med. 1998; 157: 677–678.

35. Kumar S.D., Emery M.J., Atkins N.D. et al. Airway mucosal blood flow in bronchial asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 153–156.

36. Kumar S.D., Brieva J.L., Danta I. et al. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 918–921.

37. Mendes E.S., Pereira A., Danta I. et al. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur. Respir. J. 2003; 21: 989–993.

38. Horvath G., Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur. Respir. J. 2006; 27: 172–187.

39. Wanner A., Horvath G., Brieva J.L. et al. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc. Am. Thorac. Soc. 2004; 1: 235–238.

40. Aziz I., Lipworth B.J. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and 2-adrenoreceptor downregulation after regular inhaled formoterol. Chest 1999; 115: 623–628.

41. Lin R.Y., Newman T.G., Sauter D. et al. Association between reported use of inhaled triamcinolone and differential shortterm responses to aerosolized albuterol in asthmatics in an emergency department setting. Chest 1994; 106: 452–457.

42. Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am. J. Respir. Crit. Care Med. 2001; 163: 32–36.

43. Rowe B.H., Vethanayagam D. The role of inhaled corticosteroids in the management of acute asthma. Eur. Respir. J. 2007; 30: 1035–1037.

44. Rodrigo G.J. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 1231–1236.

45. Pansegrouw D.F. Acute resistant asthma caused by excessive β2 -adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone. S. Afr. Med. J. 1992; 82: 179–182.

46. Rodrigo G.J., Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 2003; 123: 1908–1915.

47. Цой А.Н., Аржакова Л.С., Архипов В.В. Фармакодинамика и клиническая эффективность ингаляционных глюкокортикостероидов у больных с обострением бронхиальной астмы. Пульмонология 2002; 3: 88–92.

48. Овчаренко С.И., Передельская О.А., Морозова Н.В., Ма2 колкин В.И. Небулайзерная терапия бронхолитиками и суспензией пульмикорта в лечении тяжелого обострения бронхиальной астмы. Пульмонология 2003; 6: 75–83.

49. Mitchell C.A., Alpers J.H., Morton S.M. et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma. Eur. Respir. J. 1995; 8 (suppl. 19): 490s.

50. Higgenbottam T.W., Britton J., Lawrence D. et al. On behalf of the Pulmicort Respules versus oral steroids: A prospective clinical trial in acute asthma. Comparison of nebulised budesonide and prednisolone in severe asthma exacerbation in adults. BioDrugs 2000; 14: 247–254.

51. Ediger D., Coskun F., Kunt Uzaslan E. et al. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks. Tuberkuloz ve Toraks Dergisi 2006; 54: 128–136.

52. Авдеев С.Н., Жестков А.В., Лещенко И.В. и др. Небулизированный будесонид при тяжелом обострении бронхиальной астмы: сравнение с системными стероидами. Мультицентровое рандомизированное контролируемое исследование. Пульмонология 2006; 4: 58–67.

53. Maltais F., Ostinelli J., Bourbeau J. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 698–703.

54. Авдеев С.Н., Суточникова О.А., Белевский А.С., Чучалин А.Г. Применение небулизированного будесонида при тяжелом обострении хронической обструктивной болезни легких. Рандомизированное контролируемое исследование. Пульмонология 2003; 5: 81–88.

55. Gunen H., Hacievliyagil S.S., Yetkin O., Gulbas G. The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur. Respir. J. 2007; 30: 399–400.

56. Toogood J.H., Baskerville J., Jennings B. et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J. Allergy Clin. Immunol. 1989; 84: 688–700.

57. British Thoracic Society and Scottish Intercollegiate Guidelines Network Guidelines on Asthma. Thorax 2003; 58 (suppl. I): i1–i94.

58. Harriman A.2M., Purcell N., Fleming S. et al. Can we mixt nebulizer solutions? Stability of drug admixtures in solutions for nebulizations. Pharm. Pract. 1996; 6: 347–348.

59. Grцnberg S., Magnusson P., Bladh N. Chemical compartibility of budesonide inhalation suspension (Pulmicort Respules) with other nebulization products. Am. J. Respir. Crit. Care Med. 2001; 163: A558.

60. McKenzie J.E., Cruz2Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann. Pharmacother. 2004; 38: 967–972.


Для цитирования:

Авдеев С.Н. Небулайзерная терапия суспензией будесонида при обострениях бронхиальной астмы и хронической обструктивной болезни легких. Пульмонология. 2007;(6):110-118.

For citation:

Avdeev S.N. Nebulized therapy with suspension of budesonide in exacerbations of asthma and chronic obstructive pulmonary disease. PULMONOLOGIYA. 2007;(6):110-118. (In Russ.)

Просмотров: 236

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)